1.

纳入研究的基本特点

Basic characteristic of included studies

First author	Year	Stage of NSCLC	Vandetanib group	Placebo group	Jadad score
NSCLC: non-small cell lung cancer.
Heymach[16]	2007	Ⅲb or Ⅳ	vandetanib+docetaxel	docetaxel	3
Natale[19]	2009	Ⅲb or Ⅳ	vandetanib	gefitinib	4
Herbst[3]	2010	Ⅲb or Ⅳ	vandetanib+docetaxel	docetaxel	4
Natale[9]	2011	Ⅲb or Ⅳ	vandetanib	erlotinib	3
de Boer RH[20]	2011	Ⅲb or Ⅳ	vandetanib+pemetrexed	pemetrexed	4